
Kodiak Sciences Inc.
- Jurisdiction
United States - LEI
254900IXI5NI8C9OQE24 - ISIN
US50015M1099 (KOD )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€177.55M - EBIT margin
0.0% - Net income
-€75.38M - Net margin
0.0%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
N/A |
| |
|
| |
|
|
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 28, 2024
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |